APLS - Apellis Pharmaceuticals, Inc.
NEXT EARNINGS:
May 5, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.50
DETAILS
HIGH:
$52.00
LOW:
$19.00
MEDIAN:
$30.50
CONSENSUS:
$33.50
UPSIDE:
51.38%
Market Cap:
2.80B
Volume:
3,028,287
Avg Volume:
2,794,335
52 Week Range:
16.1-30.48
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.24
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
705
IPO Date:
2017-11-09
EPS (TTM):
N/A
P/E Ratio:
N/A
Revenue (TTM):
689.38M
Total Assets:
1.08B
Total Debt:
112.70M
Cash & Equiv:
466.23M
Rev Growth (5Y):
22.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
0.30
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-30 | $1.67 | $1.03 | +62.1% | $458.6M | $199.3M | +130.1% |
| 2025-07-31 | $-0.33 | $-0.44 | +25.0% | $178.5M | $372.0M | -52.0% |
| 2025-05-07 | $-0.74 | $-0.36 | -105.6% | $166.8M | $209.2M | -20.3% |
| 2025-02-28 | $-0.29 | $-0.37 | +21.6% | $212.5M | $199.1M | +6.7% |
| 2024-11-05 | $-0.46 | $-0.32 | -43.8% | $196.8M | $191.9M | +2.6% |
| 2024-08-01 | $-0.28 | $-0.33 | +15.2% | $199.7M | $191.1M | +4.5% |
| 2024-05-07 | $-0.54 | $-0.54 | 0.0% | $172.3M | $163.3M | +5.5% |
| 2024-02-27 | $-0.73 | $-0.66 | -10.6% | $146.4M | $143.6M | +1.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 689.38M | 781.37M | 396.59M | 75.42M | 66.56M | 250.65M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | 22.39M | (197.88M) | (528.63M) | (652.17M) | (746.35M) | (344.87M) | (304.71M) | (127.50M) | (51.01M) | (27.12M) | (46.52M) | (10.79M) |
| EPS | 0.00 | -1.60 | -4.45 | -6.15 | -8.84 | -4.59 | -4.98 | -2.34 | -1.49 | -1.50 | -2.57 | -0.60 |
| Total Assets | 1.08B | 885.05M | 788.73M | 760.22M | 881.76M | 960.57M | 389.24M | 203.53M | 182.13M | 27.43M | 38.18M | 14.31M |
| Total Debt | 112.70M | 469.78M | 110.93M | 112.71M | 210.22M | 377.73M | 157.03M | 27.04M | 26.39M | 0 | 0 | 0 |
| Cash & Equivalents | 466.23M | 411.29M | 351.19M | 551.80M | 640.19M | 565.78M | 351.99M | 176.27M | 175.64M | 24.86M | 36.00M | 13.62M |
| Operating Cash Flow | 45.33M | (87.87M) | (594.74M) | (513.75M) | (563.13M) | (160.49M) | (211.13M) | (131.24M) | (46.60M) | (26.00M) | (18.86M) | (9.95M) |
| Free Cash Flow | 45.33M | (88.27M) | (595.51M) | (515.27M) | (564.23M) | (165.91M) | (212.83M) | (131.24M) | (46.60M) | (26.00M) | (18.86M) | (9.97M) |
| FCF per Share | N/A | -0.71 | -5.02 | -4.86 | -6.68 | -2.21 | -3.42 | -2.41 | -1.36 | -1.44 | -1.04 | -0.55 |
| Book Value | 370.15M | 228.54M | 194.52M | 169.87M | 198.66M | 204.56M | 34.23M | 160.97M | 148.94M | 23.79M | 34.98M | 13.22M |
| Cash & ST Investments | 466.23M | 416.14M | 352.30M | 551.80M | 701.23M | 877.65M | 351.99M | 176.27M | 175.64M | 24.86M | 36.00M | 13.62M |
| ROC Equity | 0.06 | -0.87 | -2.72 | -3.84 | -3.76 | -1.69 | -8.90 | -0.79 | -0.34 | -1.14 | -1.33 | -0.82 |